×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Mechanism: Neuroresilience Mechanisms and Evidence
mechanism
5,775 words
KG: Neuroresilience Mechanisms and Evidence
Contents
Neuroresilience Mechanisms and Evidence
⚙
Mechanism Info
Name
Neuroresilience Mechanisms and Evidence
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (31)
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
Aquaporin-4 Polarization Rescue
Score: 0.73
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.70
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.62
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.56
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
← Prev
pg 2/2
Related Analyses (29)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Show 24 more
Related Experiments (29)
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Gandouling protection against brain injury in Wilson's disea
validation · proposed · Score: 0.90
AMPK knockdown validation experiment
exploratory · proposed · Score: 0.88
iPSC-NPC transplantation in ICH animal model
validation · proposed · Score: 0.85
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
Epigenetic Clocks in Neurodegeneration — Causal Drivers or P
validation · completed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
Show 24 more
See Also (15)
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
Alzheimer's Disease Circadian Rhythm and Sleep-Wake Cyc
company · Pages share 4 hypotheses
VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers
biomarker · Pages share 4 hypotheses
Microglia in Alzheimer's Disease Neurodegeneration
cell · Pages share 4 hypotheses
Alzheimer's Disease Adenosine Receptor and Purinergic S
company · Pages share 4 hypotheses
Alzheimer's Disease Calcium Channel and Homeostasis The
company · Pages share 4 hypotheses
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 4 hypotheses
Speech and Cognitive Biomarkers for Alzheimer's Disease
biomarker · Pages share 4 hypotheses
Blood p-Tau181 and p-Tau217 Elevated in Systemic Amyloi
biomarker · Pages share 4 hypotheses
Microglia in Alzheimer's Disease Neurodegeneration
redirect · Pages share 4 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 4 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 4 hypotheses
Alzheimer's Disease Apolipoprotein and Lipid Transport
company · Pages share 4 hypotheses
Alzheimer's Disease Calcium Homeostasis and Channel Mod
company · Pages share 4 hypotheses
Alzheimer's Disease Copper Homeostasis and Metal Transp
company · Pages share 4 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.